BiotechTube

Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6)

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertension

Conditions

Hypertension, Hyperlipidemia

Trial Timeline

Nov 1, 2011 → May 1, 2012

NCT ID
NCT01609907

About Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6)

Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6) is a phase 1 stage product being developed by Yuhan for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01609907. Target conditions include Hypertension, Hyperlipidemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01609907Phase 1Completed

Competing Products

20 competing products in Hypertension

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
L04RD1 + L04TD3CelltrionPhase 1
33
Azilsartan MedoxomilCelltrionPre-clinical
23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
77
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
85
Telmisartan + Amlodipine + ChlorthalidoneYuhanPhase 1
33
Temisartan/Amlodipine+Rosuvastatin + YHP1604YuhanPhase 1
33
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+RosuvastatinYuhanPhase 3
77
Amlodipine + ValsartanYuhanApproved
85
Duowell® + TelmisartanYuhanApproved
85
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
77
YH22189 + Twynsta 80/10mg + Crestor 20mgYuhanPhase 1
33
OM 40 + OM/HCTZ 40/12.5Daiichi SankyoPhase 3
77

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85